CD8A and breast carcinoma: Meanwhile, MLN8237 also could impair T cell-mediated antitumor immune response through reducing the number of CD3+ and CD8+ T cells infiltrated in vivo with 4T1 mouse breast cancer cells (Figure 5), which exerted immunosuppressive effects.